Stockscreener 앱 받기
3.44
19.86%
0.57
시장 영업 전:
3.51
0.07
+2.03%
Replimune Group Inc 주식(REPL)의 최신 뉴스
MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA - Streetwise Reports
What's Going On With Replimune Stock On Tuesday? - Sahm
REPL nosedives as FDA chief stands firm against melanoma treatment: ‘I don’t work for Replimune’ - MSN
What's going on with Replimune stock on Tuesday? - MSN
FDA Commissioner Makary defends agency’s decision on Replimune’s drug, CNBC reports - hi99.com
FDA head Makary defends drug application rejections amid criticism - Seeking Alpha
REPL Stock Plunges As FDA Rejects Key Melanoma Therapy - StocksToTrade
REPL Nosedives As FDA Chief Stands Firm Against Melanoma Treatment: ‘I Don’t Work For Replimune…’ - Stocktwits
REPL Stock Plunges As FDA Rejection Triggers Legal And Wall Street Backlash - timothysykes.com
FDA Commissioner Makary defends agency's decision on Replimune's drug, CNBC reports - Reuters
FDA Commissioner Makary defends agency's decision on Replimune's drug - marketscreener.com
Fda's Makary on Replimune's Drug Says If the Clinical Trials Show That It Works, It's Going to Get ApprovedCnbc - marketscreener.com
Fda's Makary on Replimune Says Three Indepndent Teams Arrived at the Same ConclusionsCnbc - marketscreener.com
Fda's Makary Defends Agency's Decision On Replimune's Cancer Drug -Cnbc - marketscreener.com
Replimune plunges after FDA rejects skin cancer drug again - MSN
REPL stock rallies in anticipation of FDA decision on skin cancer drug - MSN
FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients - The Cancer Letter
Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 12.8% - MarketBeat
Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz - The National Law Review
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - PR Newswire
Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, In - The National Law Review
Replimune Group (REPL) price target decreased by 59.94% to 5.04 - MSN
Street sours on Replimune as stock hits all-time low on melanoma drug rejection - MSN
MSN Money - MSN
MSN - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Gro - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Shareholders to Connect - ACCESS Newswire
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - FinancialContent
Opinion | Replimune’s Fate Is Worse Than a Tragedy - WSJ
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Shareholders to Reach Out - ACCESS Newswire
Replimune under pressure as FDA rejects lead asset again - MSN
2026-04-27 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Shareholders to Reach Out | NDAQ:REPL | Press Release - Stockhouse
Replimune brings 3-year melanoma survival data to ASCO oral session - Stock Titan
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
200+ Mass. biotech employees were laid off last week. That may only be the beginning - MSN
Wedbush Upgrades Replimune Group (REPL) - MSN
Replimune plans layoffs as FDA rejects cancer drug - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
REPL Stock Crashes As FDA Rejects RP1 Melanoma Bid Again - StocksToTrade
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
REPL Stock Collapses As FDA Rejects RP1 Melanoma Bid - StocksToTrade
REPL Stock Collapses As FDA Rejection Triggers Downgrades - StocksToTrade
1.77%
0.25%
자본화:
|
볼륨(24시간):